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http://dx.doi.org/10.1016/j.jfma.201Systemic fungal infection continues to be a major cause of mortality in extremely low-birth-
weight premature infants. Amphotericin B has been recommended as the primary treatment;
however, its use is limited due to drug-induced nephrotoxicity and amphotericin B-resistant
candidemia. Caspofungin therapy was initiated in seven extremely premature infants at 23
and 24 weeks’ gestation with persistent systemic candidiasis despite liposomal amphotericin
B treatment. The gestational age was 23þ1e24þ6 weeks, and birth weight was 530e825 g.
Of the seven patients, the peripheral blood cultures of six patients were positive for Candida
parapsilosis and one had positive culture for Candida albicans. The dosage of caspofungin was
2 mg/kg/day, and the mean treatment duration was 14 days. All of the persistent candidemia
resolved on caspofungin therapy. There was no recurrent candidemia after discontinuing cas-
pofungin. There were no adverse effects, hepatotoxicity, nephrotoxicity, anemia, or thrombo-
cytopenia. Caspofungin successfully treated persistent candidemia in extremely premature
infants at 23 and 24 weeks’ gestational age.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Fungal infection continues to be a major cause of mortality
among extremely low-birth-weight infants (ELBWIs) and is
the third most common cause of late-onset sepsis inhave no conflicts of interest
t of Pediatrics, Busan Paik
cine, 75 Bokji-ro, Busanjin-gu,
il.net (G.W. Jeon).
ight ª 2014, Elsevier Taiwan LLC
4.01.003neonates after Gram-positive sepsis and Gram-negative
sepsis.1,2 The risk of systemic candidiasis and mortality is
inversely proportional to gestational age and birth weight.1
The ELBWIs have numerous risk factors of systemic candi-
diasis.3 Amphotericin B has been recommended as the
primary treatment of choice. However, it causes infusion-
related toxicities and serious renal toxicity, especially in
ELBWIs with immature renal function.4 Liposomal ampho-
tericin B did not cause nephrotoxicity in a 10-year cohort of
preterm infants with birth weight <1500 g.5 Therefore,
liposomal amphotericin B is sometimes used as the first-line
agent for systemic candidiasis of ELBWI in certain neonatal& Formosan Medical Association. All rights reserved.
192 G.W. Jeon, J.B. Sinintensive care units (NICUs) in Korea. However, amphoter-
icin B- or liposomal amphotericin B-resistant candidemia
has been on the rise.6
Caspofungin (an echinocandin), a newer type of anti-
fungal agent, inhibits fungal 1,3-beta-glucan synthesis, and
is highly selective to fungal cells because 1,3-beta-glucan
synthesis does not occur inmammalian cell membrane; thus,
echinocandins are safe and well tolerated with fewer side
effects.7,8 To date, however, there is limited experience
with the use of caspofungin in extreme preterm infants.
This study presents our experience of caspofungin
therapy in seven extremely premature infants at 23 and 24
weeks’ gestation with persistent systemic candidiasis
despite liposomal amphotericin B treatment.Patients and methods
The protocol of this study was reviewed and approved by
the Institutional Review Board of the Busan Paik Hospital.
Data were collected retrospectively from medical records.
Informed parental consent was obtained before caspo-
fungin administration. Systemic candidiasis was diagnosed
based on clinical signs of systemic infection with a positive
blood culture for Candida species. Blood culture was ob-
tained from a peripheral vein. Central catheters were
removed immediately after systemic candidiasis was
diagnosed.
Liposomal amphotericin B (AmBisome; Gilead Sciences
International Ltd., Cambridge, UK) was administered at a
dose of 5 mg/kg/day. Caspofungin (CANCIDAS; Merck & Co.,
Inc. Sumneytown Pike, West Point, PA, USA) was adminis-
tered at a dose of 2 mg/kg/day. Demographic factors were
evaluated to determine the factors related to systemic
candidiasis and treatment outcome.
The efficacy was evaluated by eradication of Candida
species, which means negative cultures after the initiation
of antifungal treatment from positive cultures. The eradi-
cation time represents the days taken to sterilize after
initiation of antifungal treatment.
The safety was evaluated based on infusion-related
adverse effects, serum biochemistry profiles, and com-
plete blood count.Results
Demographics and patient characteristics
A total of seven extremely premature infants born at 23
and 24 weeks’ gestation with systemic candidiasis resistant
to liposomal amphotericin B were treated with caspo-
fungin. The gestational age was 23þ6 weeks (23þ1e24þ6
weeks) and birth weight was 640 g (530e825 g). The pe-
ripheral blood cultures were positive for Candida para-
psilosis in six, and Candida albicans in one. There was no
vegetation in the heart on echocardiography. Ventriculitis
and fungal microabscess were not found on the brain ul-
trasound. Renal fungal ball and microabscess were not
identified on the abdominal ultrasound. Renal stones were
identified in three patients who had negative urinecultures. The demographic and patient characteristics, and
efficacy are shown in Table 1.
All of them had respiratory distress syndrome and
needed prolonged ventilator care. All of them had bron-
chopulmonary dysplasia and patent ductus arteriosus. An
umbilical catheter had been inserted for 7 days and a
peripherally inserted central catheter for 44 days. Total
parenteral nutrition had been infused for 47 days. Five
received systemic antibiotic treatment before caspofungin
therapy. Two received postnatal steroids therapy.
Efficacy
The mean cumulative amount and the mean duration of
liposomal amphotericin B administered before caspofungin
were 90 mg/kg (30e180 mg/kg) and 18 days (6e36 days),
respectively. All cases of persistent candidemia resolved on
caspofungin therapy. The mean cumulative dose of caspo-
fungin was 27.7 mg/kg (4e48 mg/kg) and the mean dura-
tion of caspofungin treatment was 14 days (2e24 days).
After initiation of caspofungin, blood cultures were sterile
after 4, 13, 4, 8, and 3 days in each patient. There was no
recurrent candidemia after the discontinuation of the cas-
pofungin therapy. Six patients survived. In Patient 7, the
blood culture could not be followed up because he passed
away within 2 days after the initiation of caspofungin.
Safety
No infusion-related adverse effects, such as bradycardia,
tachycardia, pyrexia, hypotension, hypertension, tachyp-
nea, and rash, were observed. Blood urea nitrogen (BUN),
creatinine, serum potassium, and urine output remained
stable. One patient (Patient 7) had hyperkalemia, elevated
BUN and serum creatinine levels before caspofungin
treatment due to sepsis. Caspofungin-induced hepatotox-
icity was not found. In Patient 2, elevated liver enzyme and
bilirubin were noted before caspofungin infusion due to
parenteral nutrition-induced cholestasis combined with
sepsis. Drug-induced anemia and thrombocytopenia were
not found. Thrombocytopenia was improved in three pa-
tients because of the eradication of Candida spp. (Table 2).
Discussion
Systemic candidiasis in preterm infants has markedly
increased due to the increased survival of extremely
immature infants.9,10 The ELBWIs are prone to systemic
fungal infection due to invasive procedures and immature
mucocutaneous barrier function and host defenses. C.
albicans had been the most prevalent pathogen of neonatal
fungal infections.11 However, non-albicans Candida species
have been on the rise. Odio et al reported that six of the 10
neonates with systemic candidiasis in their study had non-
albicans Candida species,6 and Natarajan et al reported
that C. parapsilosis was the most common Candida species
in neonates,10 which was the predominant pathogen in this
study too.
The resistance rates to amphotericin B and liposomal
amphotericin B were 2e7% in 1999,12 and recent studies
report that resistance to these drugs is increasing. As a
Table 1 Demographic and patient characteristics, and efficacy.
Pt GAa BWtb Isolate Sites of infection Liposomal
amphotericin Bc
Caspofungind Outcome Start
daye
Sterilizationf
1 23þ3 530 C. parapsilosis Blood 65 (13 d) 24 (12 d) Cure 38/50 4
2 23þ2 615 C. parapsilosis Blood 180 (36 d) 42 (21 d) Cure 17/53 13
3 24þ0 550 C. parapsilosis,
C. albicans
Blood, urine 110 (22 d) 32 (16 d) Cure 14/36 4
4 24þ1 670 C. parapsilosis Blood, urine,
tracheal aspirate
105 (21 d) 14 (7 d) Cure 29/50 0
5 24þ3 725 C. parapsilosis Blood 75 (15 d) 30 (15 d) Cure 20/35 8
6 24þ6 825 C. albicans Blood, urine,
tracheal aspirate
30 (6 d) 48 (24 d) Cure 7/13 3
7 23þ1 570 C. parapsilosis Blood 65 (13 d) 4 (2 d) Died 10/23
a Gestational age (weekþday).
b Birth weight (g).
c Cumulative amount and the duration of administered liposomal amphotericin B before caspofungin treatment (mg/kg, days).
d Cumulative amount and the duration of administered caspofungin (mg/kg, days).
e Postnatal days when the drugs were initiated (liposomal amphotericin B/caspofungin).
f Days required to sterile blood culture after initiation of caspofungin (days).
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well tolerated than amphotericin B and the lipid formula-
tion of amphotericin B are needed. Caspofungin was
approved by the Food and Drug Administration for the
treatment of fungal infection refractory to amphotericin B
or lipid formulations of amphotericin B only in adults and
not in children. Caspofungin was tried in children based on
the successful results in adults. It was effective and safe in
immunocompromised pediatric patients.13 In a multicenter
prospective study in Spain, C. parapsilosis isolates were
susceptible to echinocandins.14
Although not yet licensed in neonates, some case reports
of caspofungin treatment in ELBWI indicate excellent
therapeutic efficacy without significant adverse effects.13
An 810-g baby boy with 25 weeks of gestation,15 a 980-g
baby boy with 27 weeks of gestation,16 and a 660-g baby
girl with 23 weeks of gestation17 had persistent C. albicans,
C. parapsilosis, and C. glabrata infection refractory toTable 2 Safety.
Pt BUNa/creatinine/potassium ALTb/ASTc/bilirub
Befored Duringe Afterf Befored Durin
1 3/0.3/4 3/0.3/3.6 4/0.47/3.6 13/35/1.8/1.3 20/3
2 7/0.18/3.6 3/0.29/4.0 4/0.48/3.1 34/113/6.1/5.1 18/7
3 4/0.41/3.6 4/0.27/4.6 5/0.31/4.3 8/28/1.4/1.1 10/2
4 13/0.32/4.1 3/0.22/4.6 9/0.06/4.7 13/29/0.7/0.3 9/22
5 4/0.47/3.7 6/0.32/4.2 8/0.41/4.8 15/25/0.3/0.2 11/2
6 52/1.79/5.0 3/0.84/5.1 10/0.49/5.2 <3/31/2.1/0.3 10/4
7 20/1.69/6.3 d d 15/31/3.7/3.2 d
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;
a Blood urea nitrogen (mg/dL); creatinine (mg/dL); potassium (mEq
b Alanine aminotransferase (U/L).
c Aspartate aminotransferase (U/L); bilirubin (mg/dL); conjugated b
d Before infusion of caspofungin.
e During infusion of caspofungin.
f After discontinuation of caspofungin.
g After red blood cell transfusion.amphotericin B, respectively. Their blood was sterilized in
only 8 days, 7 days, and 72 hours following caspofungin
treatment, respectively. In another study, persistently
culture-positive blood was sterilized in only 4.3 days
following caspofungin therapy.6
The adequate dosage of caspofungin treatment is not
clearly defined in neonates, because it is not yet licensed
for neonates and there is a lack of prospective randomized
controlled studies. Odio et al used 1 mg/kg/day for 2 days,
followed by 2 mg/kg/day6; Natarajan et al used 1.5 mg/kg/
day for 1 day, followed by 1 mg/kg/day10; Yalaz et al used a
loading dose of 5 mg/kg/day (50 mg/m2/day) for 3 days,
followed by 2.5 mg/kg/day (25 mg/m2/day)16; and we used
2 mg/kg/day without loading dose. The optimal treatment
duration of caspofungin in neonates remains uncertain,
too. A sufficiently long treatment period is required to
prevent relapse of candidemia especially in infection foci
such as vegetations of fungal balls. Therefore, thein/conjugated bilirubin Hemoglobin/platelet
ge Afterf Befored Duringe Afterf
5/1.5/1.2 20/44/1.6/1.0 7.9/71 7.8/72 7.2/99
6/7.3/6.3 25/121/7.8/6.6 9.5/89 9.9/80 9.3/160
8/0.7/0.5 10/27/0.6/0.4 9.3/59 8.7/138 10.8/193
/1.1/0.9 9/35/0.8/0.6 5.9/340 10.5g/334 10.3/268
3/0.2/<0.1 10/20/0.1/0.1 10.8/343 9.2/385 8.2/725
1/0.3/0.1 12/24/0.1/0.1 10.6/127 10.1/125 8.0/104
d 7.0/103 9.1/70 d
BUN Z blood urea nitrogen.
/L).
ilirubin (mg/dL); hemoglobin (g/dL); platelet (109/L).
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didemia is about 3 weeks.18,19
Azole antifungal agents (i.e., fluconazole, voriconazole)
are metabolized by the hepatic cytochrome P450 system.
There can be numerous drug interactions. However, cas-
pofungin is not metabolized by the hepatic cytochrome
P450 system, and therefore drug interactions are minimal.
This is an important advantage of caspofungin because
preterm infants in the NICUs use many concomitant drugs.7
Caspofungin is mainly metabolized by the liver, and
therefore, there is no need of dose adjustment in renal
insufficiency.20
In summary, caspofungin successfully treated persistent
candidemia despite liposomal amphotericin B treatment in
extremely premature infants born at 23 and 24 weeks’
gestation. Caspofungin can be thought as an alternative for
the treatment of systemic candidiasis in extreme prema-
turity when there is persistent, or liposomal amphotericin
B-resistant candidemia. The limitations of this retrospec-
tive study are the small number of patients (only seven
ELBWIs) and there is no comparison with a liposomal
amphotericin B group, or a placebo group. To understand
the pharmacokinetics and safety of caspofungin before
widespread use, a prospective randomized controlled study
with a larger number of ELBWIs is needed.
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